Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy

Joseph A. Sparano, Robert J. Gray, Della F. Makower, Kathy S. Albain, Thomas J. Saphner, Sunil S Badve, Lynne I. Wagner, Virginia G. Kaklamani, Maccon M. Keane, Henry L. Gomez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Deborah L. Toppmeyer, Adam M. Brufsky, Matthew P. Goetz, Jeffrey L. Berenberg, Catalin Mahalcioiu, Christine Desbiens, Daniel F. Hayes, Elizabeth C. Dees, Charles E. Geyer, John A. Olson, William C Wood, Tracy Lively, Soonmyung Paik, Matthew J. Ellis, Jeffrey Abrams, George W. Sledge

Open source

DOI
10.1001/jamaoncol.2019.4794
Published
2020-03-01
Container
JAMA Oncology
Publisher
American Medical Association (AMA)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1001/jamaoncol.2019.4794,
  title = {Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy},
  author = {Joseph A. Sparano and Robert J. Gray and Della F. Makower and Kathy S. Albain and Thomas J. Saphner and Sunil S Badve and Lynne I. Wagner and Virginia G. Kaklamani and Maccon M. Keane and Henry L. Gomez and Pavan S. Reddy and Timothy F. Goggins and Ingrid A. Mayer and Deborah L. Toppmeyer and Adam M. Brufsky and Matthew P. Goetz and Jeffrey L. Berenberg and Catalin Mahalcioiu and Christine Desbiens and Daniel F. Hayes and Elizabeth C. Dees and Charles E. Geyer and John A. Olson and William C Wood and Tracy Lively and Soonmyung Paik and Matthew J. Ellis and Jeffrey Abrams and George W. Sledge},
  year = {2020},
  journal = {JAMA Oncology},
  doi = {10.1001/jamaoncol.2019.4794},
  url = {https://doi.org/10.1001/jamaoncol.2019.4794}
}

RIS

TY  - JOUR
TI  - Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy
AU  - Joseph A. Sparano
AU  - Robert J. Gray
AU  - Della F. Makower
AU  - Kathy S. Albain
AU  - Thomas J. Saphner
AU  - Sunil S Badve
AU  - Lynne I. Wagner
AU  - Virginia G. Kaklamani
AU  - Maccon M. Keane
AU  - Henry L. Gomez
AU  - Pavan S. Reddy
AU  - Timothy F. Goggins
AU  - Ingrid A. Mayer
AU  - Deborah L. Toppmeyer
AU  - Adam M. Brufsky
AU  - Matthew P. Goetz
AU  - Jeffrey L. Berenberg
AU  - Catalin Mahalcioiu
AU  - Christine Desbiens
AU  - Daniel F. Hayes
AU  - Elizabeth C. Dees
AU  - Charles E. Geyer
AU  - John A. Olson
AU  - William C Wood
AU  - Tracy Lively
AU  - Soonmyung Paik
AU  - Matthew J. Ellis
AU  - Jeffrey Abrams
AU  - George W. Sledge
PY  - 2020
JO  - JAMA Oncology
DO  - 10.1001/jamaoncol.2019.4794
UR  - https://doi.org/10.1001/jamaoncol.2019.4794
ER  - 

APA

Sparano, J. A., Gray, R. J., Makower, D. F., Albain, K. S., Saphner, T. J., Badve, S. S., Wagner, L. I., Kaklamani, V. G., Keane, M. M., Gomez, H. L., Reddy, P. S., Goggins, T. F., Mayer, I. A., Toppmeyer, D. L., Brufsky, A. M., Goetz, M. P., Berenberg, J. L., Mahalcioiu, C., Desbiens, C., Hayes, D. F., Dees, E. C., Geyer, C. E., Olson, J. A., Wood, W. C., Lively, T., Paik, S., Ellis, M. J., Abrams, J., & Sledge, G. W. (2020). Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2019.4794

Source records